{"mainPropery":{"diseaseId":9442,"diseaseName":"Glycogen storage disease type 3","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9442/glycogen-storage-disease-type-3","synonyms":["Forbes disease","Cori disease","Limit dextrinosis","Amylo-1,6-glucosidase deficiency","Glycogen debrancher deficiency"],"synonyms-with-source":[{"name":"Forbes disease"},{"name":"Cori disease"},{"name":"Limit dextrinosis"},{"name":"Amylo-1,6-glucosidase deficiency"},{"name":"Glycogen debrancher deficiency"}],"identifiers":[{"identifierType":"OMIM","identifierId":"232400"},{"identifierType":"ORPHANET","identifierId":"366"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":6,"diseaseTypeName":"Digestive Diseases","source":"Orphanet"},{"diseaseTypeId":4,"diseaseTypeName":"Heart Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":138,"resourceName":"Metabolic Support UK","abbreviation":"","address1":"5 Hilliards Court","address2":"Sandpiper Way","address3":"Chester Business Park","address4":"","address5":"","city":"Chester","state":"","zip":"CH4 9QP","country":"United Kingdom","phone":"0845 241 2173","tty":"","tollFree":"0800 652 3181 ","fax":"","email":"https://www.metabolicsupportuk.org/contact-us","url":"https://www.metabolicsupportuk.org","freeText":""},{"resourceID":302,"resourceName":"Association for Glycogen Storage Disease UK","abbreviation":"AGSD-UK","address1":"PO Box 1232","address2":"Bristol","address3":"BS48 9DD","address4":"","address5":"","city":"","state":"","zip":"","country":"United Kingdom","phone":"0300 123 2790","tty":"","tollFree":"","fax":"","email":"https://agsd.org.uk/contact/message-us2/","url":"http://www.agsd.org.uk/","freeText":""},{"resourceID":675,"resourceName":"Children's Fund for Glycogen Storage Disease Research, Inc.","abbreviation":"","address1":"20 Sherwood Lane","address2":"","address3":"","address4":"","address5":"","city":"Cheshire","state":"CT","zip":"06410","country":"United States","phone":"203-272-7744","tty":"","tollFree":"","fax":"","email":"info@curegsd.org","url":"http://www.cureGSD.org","freeText":""},{"resourceID":4278,"resourceName":"International Association for Muscle Glycogen Storage Disease","abbreviation":"IamGSD","address1":"746 4th Avenue","address2":"","address3":"","address4":"","address5":"","city":"San Francisco","state":"CA","zip":"94118","country":"United States","phone":"","tty":"","tollFree":"","fax":"","email":"info@iamgsd.org","url":"https://www.iamgsd.org/","freeText":"Contact form: https://www.iamgsd.org/contact-us"}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/232400' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=232400' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Glycogen storage disease type 3. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-iii' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Glycogen storage disease type 3. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0017922' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/396/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1531,"resourceId":2162,"resourceName":"Medscape Reference","descriptionText":"<a href='http://emedicine.medscape.com/article/119597-overview' target='_blank'>Medscape Reference</a> provides information on this topic. You may need to register to view the medical textbook, but registration is free.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=366' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/books/NBK26372/' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1702,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='https://www.orpha.net/data/patho/Pro/en/Emergency_BIMDG_GSDType3-enPro15.pdf' target='_blank'>Orphanet Emergency Guidelines</a> is an article which is expert-authored and peer-reviewed that is intended to guide health care professionals in emergency situations involving this condition. &nbsp;","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/Orphanet:366' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":4130,"questionText":"What is glycogen storage disease type 3?","answerText":"<strong>Glycogen storage disease type 3</strong> (GSDIII) is an inherited disorder caused by the buildup of glycogen in the body's cells. This buildup impairs the function of certain organs and tissues, especially the liver and muscles. Symptoms typically begin in infancy and may include <a href=\"http://www.nlm.nih.gov/medlineplus/hypoglycemia.html\" target=_blank>hypoglycemia</a>, hyperlipidemia (excess of fats in the blood), and elevated blood levels of liver enzymes; later symptoms may include <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003275.htm\" target=_blank>hepatomegaly</a>, chronic liver disease (<a href=\"http://www.nlm.nih.gov/medlineplus/cirrhosis.html\" target=_blank>cirrhosis</a>) and liver failure later in life. Some individuals have short stature&nbsp;and&nbsp;noncancerous (benign) tumors called adenomas in the liver. GSDIII is cause by&nbsp;<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutations</a> in the <a href=\"http://ghr.nlm.nih.gov/gene/AGL\" target=_blank>AGL</a> gene and is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner.[3088] Treatment typically includes a high-protein diet with cornstarch supplementation to maintain a normal level of glucose in the blood.[3089] GSDIII is divided into types IIIa, IIIb, IIIc, and IIId; types IIIa and IIIc mainly affect the liver and muscles, and GSD types IIIb and IIId typically affect only the liver.[3088]","dateModified":"2012-02-13T12:19:00"},"basicQuestions":[{"questionId":5962,"questionText":"What are the signs and symptoms of glycogen storage disease type 3?","answerText":"In infancy, individuals with&nbsp;glycogen storage disease type 3 (GSDIII) may have low blood sugar (<a href=\"http://www.nlm.nih.gov/medlineplus/hypoglycemia.html\" target=_blank>hypoglycemia</a>),&nbsp;increased amounts of fats in the blood (hyperlipidemia), and elevated levels of liver enzymes in the blood.[4959] Hypoglycemia may cause occasional seizures in some individuals.[4961] As they age, children usually develop an enlarged liver (hepatomegaly), which can cause the abdomen to protrude. Liver size&nbsp;may return to normal during adolescence, but some affected individuals develop chronic liver disease&nbsp;and subsequent liver failure years later. Individuals often have&nbsp;delayed&nbsp;growth due to their liver problems, which can lead to <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/003271.htm\" target=_blank>short stature</a>. They may also have difficulty fighting infections, and may experience unusually frequent nosebleeds.&nbsp; A small percentage of individuals develop benign (non-cancerous)&nbsp;tumors in the liver called <a href=\"http://www.merriam-webster.com/medlineplus/adenoma\" target=_blank>adenomas</a>.[4959][4960]<br><br>GSD types IIIa and IIIc typically affect both the liver and muscles, while&nbsp;types IIIb and IIId typically affect only the liver. Individuals with type IIIa may develop <a href=\"http://www.merriam-webster.com/medlineplus/myopathy\" target=_blank>myopathy</a> in both the heart and skeletal muscles later in life.&nbsp;The first signs and symptoms of this are typically poor muscle tone (hypotonia) and mild myopathy in early childhood. The myopathy may become severe by early to mid-adulthood.[4959]","dateModified":"2012-02-13T12:16:00","resourceClassificationName":"Symptoms","references":[{"referenceId":4959,"authors":"","articleTitle":"Glycogen storage disease type III","bookWebsiteJournalTitle":"Genetics Home Reference","date":"September 2010","url":"http://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-iii","dateAccessed":"2012-02-13T00:00:00"},{"referenceId":4960,"authors":"","articleTitle":"Forbes Disease","bookWebsiteJournalTitle":"NORD","date":"October 12, 2007","url":"http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/396/viewAbstract","dateAccessed":"2012-02-13T00:00:00"},{"referenceId":4961,"authors":"Roseline Froissart","articleTitle":"Glycogen debranching enzyme deficiency","bookWebsiteJournalTitle":"Orphanet","date":"September 2009","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=366","dateAccessed":"2012-02-13T00:00:00"}]},{"questionId":5963,"questionText":"What causes glycogen storage disease type 3?","answerText":"Glycogen storage disease type 3 (GSDIII) is caused by changes (<a href=\"http://www.genome.gov/glossary/index.cfm?id=134\" target=_blank>mutations</a>) in the <a href=\"http://ghr.nlm.nih.gov/gene/AGL\" target=_blank><em>AGL</em></a> gene. This gene provides instructions for making the glycogen debranching enzyme, which is involved in the breakdown of glycogen -&nbsp;an important source of stored energy in the body. Most mutations in the <em>AGL</em> gene lead to production of a non-working form of the&nbsp;glycogen debranching enzyme; these mutations are usually responsible for causing GSD types IIIa and IIIb. The mutations in the <em>AGL</em> gene&nbsp;that cause types IIIc and IIId presumably lead to the production of glycogen debranching enzyme with&nbsp;reduced function. All <em>AGL</em>&nbsp;mutations, however,&nbsp;lead to the increased buildup of abnormal, partially broken down glycogen within cells. This buildup damages tissues and&nbsp;organs in the body, thereby causing the signs and symptoms of GSDIII.[4959]","dateModified":"2012-02-13T11:02:00","resourceClassificationName":"Cause","references":[{"referenceId":4959,"authors":"","articleTitle":"Glycogen storage disease type III","bookWebsiteJournalTitle":"Genetics Home Reference","date":"September 2010","url":"http://ghr.nlm.nih.gov/condition/glycogen-storage-disease-type-iii","dateAccessed":"2012-02-13T00:00:00"}]},{"questionId":5964,"questionText":"How is glycogen storage disease type 3 inherited?","answerText":"Glycogen storage disease type 3 (GSDIII) is inherited in an&nbsp;<a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=_blank>autosomal recessive</a> manner. This means that mutations in both copies of the disease-causing gene (usually one inherited from each parent) are necessary to cause the condition. Individuals with one abnormal copy of the gene are referred to as carriers; carriers are unaffected and&nbsp;typically do not show any signs or symptoms of the condition. When two carriers&nbsp;for an autosomal recessive condition have children together, each child has a 25% (1 in 4) risk to have the condition, a 50% (1 in 2) risk to be a carrier like each of his/her parents, and a 25% chance to not be a carrier <em>and</em> not have the condition.","dateModified":"2012-02-13T11:08:00","resourceClassificationName":"Inheritance","references":[]},{"questionId":4131,"questionText":"How is glycogen storage disease type 3 diagnosed?","answerText":"Glycogen storage disease type 3 (GSDIII) should be suspected when three main features are present:&nbsp;hepatomegaly (enlarged liver), ketotic hypoglycemia (low blood sugar accompanied by <a href=\"http://ghr.nlm.nih.gov/glossary=ketosis\" target=_blank>ketosis</a>), and elevated serum concentration of transaminases (a type of enzyme) and <a href=\"http://www.labtestsonline.org/understanding/analytes/ck/test.html\" target=_blank>CK</a>.&nbsp;Debranching enzyme activity (which is deficient in individuals with the condition) can be measured in a&nbsp;liver biopsy, but this is now not typically&nbsp;necessary for diagnosis.&nbsp;Genetic testing of the&nbsp;<a href=\"http://ghr.nlm.nih.gov/gene/AGL\" target=_blank>AGL</a> gene, the only gene known to be associated with GSDIII, confirms the diagnosis.[3089]","dateModified":"2012-02-13T12:19:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":3089,"authors":"Aditi Dagli, Christiaan P Sentner, David A Weinstein","articleTitle":"Glycogen storage disease type III","bookWebsiteJournalTitle":"GeneReviews","date":"October 21, 2010","url":"http://www.ncbi.nlm.nih.gov/books/NBK26372/","dateAccessed":"2011-03-02T00:00:00"}]},{"questionId":4132,"questionText":"How might glycogen storage disease type 3 be treated?","answerText":"There is not currently a cure for&nbsp;for glycogen storage disease type 3 (GSDIII). In some cases, diet therapy is helpful. Strict adherence to a dietary regimen may reduce liver size, prevent hypoglycemia (low blood sugar),&nbsp;help to reduce symptoms, and allow for growth and development.[3090] Management typically includes&nbsp;a high-protein diet with cornstarch supplementation to maintain a normal level of glucose in the blood.&nbsp;In infancy, feeding every three to four hours is typically recommended. Toward the end of the first year of life, cornstarch is usually tolerated and can be used to avoid hypoglycemia. A high-protein diet prevents breakdown of muscle protein in times of glucose need and preserves skeletal and cardiac muscles. Skeletal and cardiac <a href=\"http://www.merriam-webster.com/medlineplus/myopathy\" target=_blank>myopathies</a>&nbsp;may be improved with high-protein diet and avoiding excessive carbohydrate intake.[3089] Liver transplantation may be indicated for patients with hepatic cancers.[3090]<br><br>Individuals seeking personal&nbsp;treatment advice should speak with their health care provider.","dateModified":"2012-02-13T11:55:00","resourceClassificationName":"Treatment","references":[{"referenceId":3089,"authors":"Aditi Dagli, Christiaan P Sentner, David A Weinstein","articleTitle":"Glycogen storage disease type III","bookWebsiteJournalTitle":"GeneReviews","date":"October 21, 2010","url":"http://www.ncbi.nlm.nih.gov/books/NBK26372/","dateAccessed":"2011-03-02T00:00:00"},{"referenceId":3090,"authors":"Wayne E Anderson","articleTitle":"Glycogen Storage Disease, Type III: Treatment & Medication","bookWebsiteJournalTitle":"eMedicine","date":"January 13, 2010","url":"http://emedicine.medscape.com/article/119597-treatment","dateAccessed":"2011-03-02T00:00:00"}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12259,"relatedDiseaseName":"Glycogen storage disease","relation":"Parent","isRare":false,"hasGardPage":false}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":9893,"phenoTypeName":"Full cheeks","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13752,"phenoTypeName":"Hypertriglyceridemia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13041,"phenoTypeName":"Hypoglycemia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10673,"phenoTypeName":"Immunodeficiency","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":8722,"phenoTypeName":"Intellectual disability, mild","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":3605,"phenoTypeName":"Short stature","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14500,"phenoTypeName":"Myopathy","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":14224,"phenoTypeName":"Broad nasal tip","percentRanges":"-"},{"phenoTypeId":4782,"phenoTypeName":"Cardiomyopathy","percentRanges":"-"},{"phenoTypeId":10499,"phenoTypeName":"Deeply set eye","percentRanges":"-"},{"phenoTypeId":11344,"phenoTypeName":"Depressed nasal bridge","percentRanges":"-"},{"phenoTypeId":5271,"phenoTypeName":"Distal amyotrophy","percentRanges":"-"},{"phenoTypeId":4319,"phenoTypeName":"Elevated hepatic transaminase","percentRanges":"-"},{"phenoTypeId":10933,"phenoTypeName":"Elevated serum creatine kinase","percentRanges":"-"},{"phenoTypeId":5690,"phenoTypeName":"Hepatic fibrosis","percentRanges":"-"},{"phenoTypeId":8115,"phenoTypeName":"Hepatomegaly","percentRanges":"-"},{"phenoTypeId":14535,"phenoTypeName":"Hyperlipidemia","percentRanges":"-"},{"phenoTypeId":14219,"phenoTypeName":"Malar flattening","percentRanges":"-"},{"phenoTypeId":12272,"phenoTypeName":"Midface retrusion","percentRanges":"-"},{"phenoTypeId":9419,"phenoTypeName":"Muscle weakness","percentRanges":"-"},{"phenoTypeId":14216,"phenoTypeName":"Thin upper lip vermilion","percentRanges":"-"},{"phenoTypeId":9817,"phenoTypeName":"Thin vermilion border","percentRanges":"-"},{"phenoTypeId":3864,"phenoTypeName":"Ventricular hypertrophy","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Glycogen_storage_disease_type_3"}